Search

Your search keyword '"Ma, Yussanne"' showing total 533 results

Search Constraints

Start Over You searched for: Author "Ma, Yussanne" Remove constraint Author: "Ma, Yussanne"
533 results on '"Ma, Yussanne"'

Search Results

151. Integrative Genomic Analysis of Cholangiocarcinoma Identifies Distinct IDH-Mutant Molecular Profiles

152. Clinical outcomes after whole genome sequencing in patients with metastatic non-small cell lung cancer.

153. Genomic profiling of pelvic genital type leiomyosarcoma in a woman with a germline CHEK2:c.1100delC mutation and a concomitant diagnosis of metastatic invasive ductal breast carcinoma

154. Correction: miR-509-3p is clinically significant and strongly attenuates cellular migration and multi-cellular spheroids in ovarian cancer

155. Comprehensive Molecular Characterization of Pheochromocytoma and Paraganglioma

157. Marked Differences in the Genomic Landscape of Pediatric Compared to Adult Acute Myeloid Leukemia: A Report from the Children's Oncology Group and NCI/COG Therapeutically Applicable Research to Generate Effective Treatments (TARGET) Initiative

158. Alteration of Chromatin Modifiers and Misregulation of Transcription Factors Define the Genomic Profile of Infant AML

159. Genomic Landscape of Pediatric Mixed Phenotype Acute Leukemia

160. A microRNA Expression-Based Model Predicts Event Free Survival in Pediatric Acute Myeloid Leukemia

161. Divergent Epigenomes in Pediatric and Adult Acute Myeloid Leukemia Implicate Cell of Origin and Transcriptional Silencing of Immune Responses As Sources of Clinically Relevant Heterogeneity: A Report from the Children's Oncology Group and NCI/COG Therapeutically Applicable Research to Generate Effective Treatments (TARGET) Initiative

162. Burkitt Lymphoma Genome Sequencing Project (BLGSP): Introduction

163. Discovery and Validation of Cell-Surface Protein Mesothelin (MSLN) As a Novel Therapeutic Target in AML: Results from the COG/NCI Target AML Initiative

164. Comprehensive Molecular Portraits of Invasive Lobular Breast Cancer

165. Significance of TP53 mutation in Wilms tumors with diffuse anaplasia : A report from the Children's Oncology Group

166. Significance of TP53 mutation in Wilms tumors with diffuse anaplasia: A report from the Children's Oncology Group

167. Significance of TP53 Mutation in Wilms Tumors with Diffuse Anaplasia: A Report from the Children's Oncology Group

168. The International Human Epigenome Consortium: A Blueprint for Scientific Collaboration and Discovery

169. Abstract 5226: Genomic analysis of pancreatic ductal adenocarcinoma in a patient with MUTYH-associated polyposis

170. Abstract LB-180: The genetic landscape of Wilms tumor

171. Rare disruptive mutations and their contribution to the heritable risk of colorectal cancer

172. A somatic reference standard for cancer genome sequencing

173. Genome-Wide Profiles of Extra-cranial Malignant Rhabdoid Tumors Reveal Heterogeneity and Dysregulated Developmental Pathways

174. Molecular Profiling Reveals Biologically Discrete Subsets and Pathways of Progression in Diffuse Glioma

175. Abstract PR02: Integrated genomic analysis of a recurrent ghost cell odontogenic carcinoma

176. MLLT1 YEATS domain mutations in clinically distinctive Favourable Histology Wilms tumours

177. Comprehensive Sequence Analysis of Relapse and Refractory Pediatric Acute Myeloid Leukemia Identifies miRNA and mRNA Transcripts Associated with Treatment Resistance - a Report from the COG/NCI-Target AML Initiative

178. TET2 Mutations Are Highly Associated with RUNX1-RUNX1T1 Translocations and NPMc+ in Childhood AML: a Report from Children's Oncology Group AAML03P1, AAML0531 and NCI/COG Target AML Initiative

179. ASXL1 and ASXL2 Mutations in Childhood AML Are Strongly Associated with t(8;21) but Do Not Independently Impact on Prognosis: A Report from the Children's Oncology Group and NCI/COG Target Initiative

180. CSF3R Mutations Represent a Novel Therapeutic Target in Pediatric AML with a High Degree of Overlap with CEBPA Mutations: a Report from COG AAML0531 and COG/NCI Target AML Initiative

181. Comprehensive Genomic and Transcript Profiling of CBL Gene in Childhood AML: A Report from Children's Oncology Group Studies AAML03P1, AAML0531 and COG/NCI Target AML Initiative

182. Discovery and Functional Validation of Novel Pediatric Specific FLT3 Activating Mutations in Acute Myeloid Leukemia: Results from the COG/NCI Target Initiative

183. The Cancer Genome Atlas Comprehensive Molecular Characterization of Renal Cell Carcinoma

184. High-resolution structural genomics reveals new therapeutic vulnerabilities in glioblastoma

185. Rearrangements in Nucleoporin Family of Genes in Childhood Acute Myeloid Leukemia: A Report from Children Oncology Group and NCI/COG Target AML Initiative

187. Burkitt Lymphoma Genome Sequencing Project (BLGSP): Integrative Genomic and Transcriptomic Characterization of Burkitt Lymphoma

189. The Molecular Taxonomy of Primary Prostate Cancer

190. Comprehensive Molecular Portraits of Invasive Lobular Breast Cancer

191. Lessons learned from the application of whole-genome analysis to the treatment of patients with advanced cancers

193. Genomic Classification of Cutaneous Melanoma

194. Implementation of Watson Genomic Analytics processing to improve the efficiency of interpreting whole genome sequencing data on patients with advanced cancers.

195. Recurrent DGCR8, DROSHA, and SIX Homeodomain Mutations in Favorable Histology Wilms Tumors

196. Epigenetic and transcriptional determinants of the human breast

198. Quiescent Sox2+ cells drive hierarchical growth and relapse in sonic hedgehog subgroup medulloblastoma

199. MAVIS: merging, annotation, validation, and illustration of structural variants.

200. Abstract 5340: Bioinformatic analyses approaches for personalized oncogenomics

Catalog

Books, media, physical & digital resources